

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: KENNETH W. LOCKE *et al.*

Application No.: 10/601,862

Group Art Unit: Not Yet Assigned

Filed: June 24, 2003

Examiner: Not Yet Assigned

For: The polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid Attorney Docket No. 215233.00500


Transmittal Letter

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. Return Receipt Postcard
2. Preliminary Amendment

Applicants believe there is no additional fee due in connection with this filing. However, to the extent required, the Commissioner is hereby authorized to charge any fees due in connection with this filing to Deposit Account 50-1710 or credit any overpayment to same.

Respectfully submitted,



Robert W. Hahl, Ph.D.
Registration No. 33,893
Gilberto M. Villacorta, Ph.D.
Registration No. 34,038

Patent Administrator
KATTEN MUCHIN ZAVIS ROSENMAN
525 West Monroe Street, Suite 1600
Chicago, Illinois 60661-3693
Facsimile: (312) 902-1061
Dated: April 28, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Application of: KENNETH W. LOCKE *et al.*

Application No.: 10/601,862

Group Art Unit: 1625

Filed: June 24, 2003

Examiner: Not Yet Assigned

For: The polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid Attorney Docket No. 215233.00500

PRELIMINARY AMENDMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION

Pages 1 – 2, rewrite section 0007 as follows:

[0007] We have observed that 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid (1), which is Example 33 in Ohashi *et al.*, is orally active for treatment of asthma and allergic diseases and that the solid compound can crystallize into several distinct polymorphs when prepared in bulk. It has been discovered that the crystallization conditions, particularly temperature, is critically important for preparing the different polymorphs.



1

Rewrite page 2, section 0009, as follows: